Celgene’s business development chief George Golumbeski quietly left his role in charge of mergers in mid-April, it was reported this week, after working in the position for nine years.
Robert Hershberg took over as executive vice presidentCelgens' and head of business development.
The news follows on from the recent departure of chief operating officer Scott Smith. Perhaps sensing turbulence at the company, investors reacted negatively to the announcement, sending Celgene's stock downwards.
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze